CLAIMS

1. A compound of formula (1):



(1)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen or C_{1-6} alkyl,

R^2 is C_{1-6} alkyl, or

R^1 and R^2 are taken together with the carbon atom to which they are attached to form C_{3-6} cycloalkyl, and

R^3, R^4, R^5, and R^6 are hydrogen.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen or C_{1-6} alkyl, and

R^2 is C_{1-6} alkyl.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:

1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide,

2-(1,2-benzoxazol-3-yl)propane-2-sulfonamide,

1-(1,2-benzoxazol-3-yl)cyclopropane-1-sulfonamide,

1-(1,2-benzoxazol-3-yl)propane-1-sulfonamide,

1-(1,2-benzoxazol-3-yl)butane-1-sulfonamide,

(1R)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide, or

(1S)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:

1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide,

2-(1,2-benzoxazol-3-yl)propane-2-sulfonamide,

1-(1,2-benzoxazol-3-yl)cyclopropane-1-sulfonamide,

(1R)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide, or

(1S)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is 1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is (1R)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide.

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is (1S)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide.

8. A pharmaceutical composition comprising the compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.9. Use of the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating and/or preventing a nervous system disease or psychiatric disease initiated by abnormality of T-type calcium channel selected from Parkinson's disease (including a symptom such as tremor, muscle stiffness/muscle rigidity, akinesia/bradykinesia, impairment of postural reflex, smell disorder, REM sleep disorder, constipation, sleep disorder, memory impairment, depression, anxiety, headache, and backache), levodopa-induced dyskinesia in Parkinson's disease, essential tremor, anxiety (including generalized anxiety disorder), neuropathic pain (including zoster-associated pain, trigeminal neuralgia, complex regional pain syndrome, peripheral neuropathy (e.g. diabetic neuropathy, leprosy, and the like), chemotherapy-induced peripheral neuropathy, phantom pain, central pain (e.g. spinal post-injury pain, post-stroke pain, and the like), pain associated with Guillain-Barre syndrome, pain associated with multiple sclerosis, pain associated with Parkinson's disease, and hyperalgesia or allodynia associated with neuropathic pain), epilepsy, or sleep disorder.

10. The use of claim 9, wherein the nervous system disease or psychiatric disease initiated by abnormality of T-type calcium channel is Parkinson's disease (including tremor, muscle stiffness/muscle rigidity, akinesia/bradykinesia, and impairment of postural reflex), essential tremor, or chemotherapy-induced peripheral neuropathy.

11. The compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof for use as a medicament.

12. The use of claim 9, wherein the medicament is to be used in combination with at least one drug selected from the drug-group classified as drugs for treating Parkinson's disease, drugs for treating essential tremor, or drugs for treating neuropathic pain.

13. A medicament comprising the compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof with at least one drug selected from the drug-group classified as drugs for treating Parkinson's disease, drugs for treating essential tremor, or drugs for treating neuropathic pain.

14. A medicament for treating nervous system disease or psychiatric disease, comprising the compound of any one of

claims 1 to 7, or a pharmaceutically acceptable salt thereof, which is used in combination with at least one drug selected from the drug-group classified as drugs for treating Parkinson's disease, drugs for treating essential tremor, or drugs for treating neuropathic pain.

15. A process for preparing a compound of formula (2):



(2)

or a pharmaceutically acceptable salt thereof, wherein

R^{1A} is hydrogen, or C_{1-6} alkyl,

R^{2A} is C_{1-6} alkyl, provided that R^{1A} and R^{2A} are different, and

R^3, R^4, R^5, and R^6 are hydrogen,

which comprises Steps 1 to 3 below,

(Step 1) reacting a compound of formula (3):



(3)

or a salt thereof, wherein R^{1A}, R^{2A}, R^3, R^4, R^5, and R^6 are as defined above, and

a compound of formula (4a) or (4b):

R^7—SH (4a) R^7-S-S-R^7 (4b)

or a salt thereof, wherein R^7 is a leaving group selected from 2-(methoxycarbonyl)ethyl, mesitylenecarbonyloxymethyl, 2-benzothiazolyl (the benzene ring of which may be substituted with 1 - 3 substituents selected independently from the group consisting of halogen, C_{1-6} alkyl (which may be substituted with 1 - 3 substituents selected independently from the group consisting of halogen, hydroxy, C_{3-6} cycloalkyl, and C_{1-3} alkoxy), C_{1-6} alkoxy (which may be substituted with 1 - 3 substituents selected independently from the group consisting of halogen, hydroxy, C_{3-6} cycloalkyl, and C_{1-3} alkoxy), hydroxy, cyano, nitro, amino (which may be substituted with 1 - 2 C_{1-3} alkyl), carboxylic acid, carbamoyl (the amino moiety of which may be substituted with 1 - 2 C_{1-3} alkyl), and C_{1-6} alkoxycarbonyl), 2-pyridyl, 2-pyrimidinyl, or 2-(trimethylsilyl)ethyl, which can release a sulfinic acid salt in the reaction

to prepare a compound of formula (5):



(5)

or a salt thereof, wherein R^{1A}, R^{2A}, R^3, R^4, R^5, R^6, and R^7 are as defined above,

(Step 2) oxidizing the compound of formula (5) or a

salt thereof to prepare a compound of formula (6):



(6)

or a salt thereof, wherein R^{1A}, R^{2A}, R^3, R^4, R^5, R^6, and R^7 are as defined above, and

(Step 3) removing R^7 from the compound of formula (6) or a salt thereof and sulfonamidating the site to prepare the compound of formula (2) or a pharmaceutically acceptable salt thereof.

16. The process of claim 15, which further comprises the following step;

(Step 4a) optically-selectively hydrolyzing a compound of formula (7):



(7)

or a salt thereof, wherein R^{1A}, R^{2A}, R^3, R^4, R^5, and R^6 are as defined in claim 15, and R^8 is C_{1-6} alkyl (which may be substituted with 1 - 3 substituents selected independently from the group consisting of halogen, hydroxy, C_{3-6} cycloalkyl, and C_{1-3} alkoxy), C_{1-6} alkoxy, or C_{1-6} alkylcarbonyloxymethoxy,

with a hydrolase selected from lipase, esterase, amidase, or protease to prepare the compound of formula (3).

17. The process of claim 15, wherein R^{1A} is hydrogen, which further comprises the following step;

(Step 4b) optically-selectively reducing a compound of formula (8):



(8)

or a salt thereof, wherein R^{2A}, R^3, R^4, R^5, and R^6 are as defined in claim 15,

with reductase and a coenzyme selected from NADH or NADPH to prepare the compound of formula (3).

18. The process of any one of claims 15 to 17, wherein R^7 is 2-benzothiazolyl.

19. The process of claim 16 or 18, wherein R^8 is methyl, and the hydrolase is lipase.

20. The process of claim 17 or 18, wherein R^{2A} is methyl, and the reductase is carbonyl reductase or alcohol dehydrogenase.

21. A process for preparing a compound of formula (2):



(2)

or a pharmaceutically acceptable salt thereof, wherein

R^{1A} is hydrogen or C_{1-6} alkyl,

R^{2A} is C_{1-6} alkyl, provided that R^{1A} and R^{2A} are different, and

R^3, R^4, R^5, and R^6 are hydrogen,

which comprises Steps 1 to 2 below,

(Step 1) reacting a compound of formula (9):



(9)

or a salt thereof, wherein R^{1A}, R^{2A}, R^3, R^4, R^5, and R^6 are as defined above, and X^{1A} is halogen, and

an optically-active compound of formula (10):



(10)

or a salt thereof, wherein P^{1A} is 2-indanol-1-yl, 2-phenylethan-1-ol-2-yl, or 3-methylbutan-1-ol-2-yl, P^{2A} is hydrogen or benzyl (the benzene ring of which may be

substituted with 1 - 5 substituents selected independently from the group consisting of halogen, C_{1-6} alkyl, and C_{1-6} alkoxy, and

dividing the prepared diastereomers to prepare a compound of formula (11):



(11)

or a salt thereof, wherein R^{1A}, R^{2A}, R^3, R^4, R^5, R^6, P^{1A}, and P^{2A} are as defined above, and

(Step 2) deprotecting the compound of formula (11) or a salt thereof to prepare the compound of formula (2) or a pharmaceutically acceptable salt thereof.

22. The process of claim 21, wherein R^{1A} is hydrogen, and R^{2A} is methyl.

23. The process of claim 21 or 22, wherein P^{1A} is 2-indanol-1-yl, and P^{2A} is hydrogen.

24. (1R)-1-(1,2-Benzoxazol-3-yl)ethane-1-sulfonamide in crystalline form of form I which is characterized by a powder x-ray diffraction pattern having diffraction angle (2θ°) peaks of 5.7° ± 0.2 and 17.3° ± 0.2°.

25. (1R)-1-(1,2-Benzoxazol-3-yl)ethane-1-sulfonamide in crystalline form of form I which is characterized by a powder x-ray diffraction pattern having four or more diffraction angle (2θ°) peaks selected from 5.7° ± 0.2, 14.1 ± 0.2°, 17.3° ± 0.2°, 19.1° ± 0.2°, 19.3 ± 0.2°, 21.6° ± 0.2°, 22.5 ± 0.2°, 23.1° ± 0.2°, 23.3° ± 0.2°, and 26.5° ± 0.2°.

26. (1R)-1-(1,2-Benzoxazol-3-yl)ethane-1-sulfonamide in crystalline form of form II which is characterized by a powder x-ray diffraction pattern having diffraction angle (2θ°) peaks of 8.7° ± 0.2° and 17.6° ± 0.2°.

27. (1R)-1-(1,2-Benzoxazol-3-yl)ethane-1-sulfonamide in crystalline form of form II which is characterized by a powder x-ray diffraction pattern having four or more diffraction angle (2θ°) peaks selected from 8.7° ± 0.2°, 13.5° ± 0.2°, 15.5° ± 0.2°, 17.6° ± 0.2°, 20.3° ± 0.2°, 21.6° ± 0.2°, 22.6° ± 0.2°, 26.2° ± 0.2°, 26.8° ± 0.2°, and 35.2° ± 0.2°.

28. (1R)-1-(1,2-Benzoxazol-3-yl)ethane-1-sulfonamide in crystalline form of form III which is characterized by a powder x-ray diffraction pattern having diffraction angle (2θ°) peaks of 11.1° ± 0.2° and 20.3° ± 0.2°.

29. (1R)-1-(1,2-Benzoxazol-3-yl)ethane-1-sulfonamide in crystalline form of form III which is characterized by a powder x-ray diffraction pattern having four or more diffraction angle (2θ°) peaks selected from 11.1° ± 0.2°, 13.8° ± 0.2°, 17.0° ± 0.2°, 20.3° ± 0.2°, 21.4° ± 0.2°, 22.1° ± 0.2°, 22.4° ± 0.2°, 24.8° ± 0.2°, 26.3° ± 0.2°, and 27.9° ± 0.2°.